Previous close | 5.02 |
Open | 5.06 |
Bid | 5.85 x 1200 |
Ask | 5.88 x 1200 |
Day's range | 4.93 - 5.95 |
52-week range | 2.00 - 11.31 |
Volume | |
Avg. volume | 2,582,522 |
Market cap | 908.242M |
Beta (5Y monthly) | 1.32 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Ocular Therapeutix (OCUL) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Q4 2023 Clearside Biomedical Inc Earnings Call
The consensus price target hints at a 34.7% upside potential for Ocular Therapeutix (OCUL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.